Study of ARTS-021 in Patients With Advanced Solid Tumors - Trial NCT05867251
Access comprehensive clinical trial information for NCT05867251 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Allorion Therapeutics Inc and is currently Not yet recruiting. The study focuses on Solid Tumors. Target enrollment is 192 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Allorion Therapeutics Inc
Timeline & Enrollment
Phase 1/2
Jul 31, 2023
Apr 30, 2026
Primary Outcome
Occurrence of Dose Limiting Toxicities (DLTs) during the first cycle,Number of Participants with Treatment Emergent Adverse Events (TEAEs) and laboratory abnormalities,Determination of Recommended Phase 2 Dose (RP2D),Objective Response Rate (ORR),Progression Free Survival (PFS),Overall Survival (OS),Time to Tumor Progression (TPP)
Summary
This study, the first clinical trial of ARTS-021, aims to determine the safety, tolerability,
 pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of
 ARTS-021 in patients with advanced solid tumors. ARTS-021 is an oral medication that inhibits
 cyclin-dependent kinase 2 (CDK 2).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05867251
Non-Device Trial